We are aware of an issue causing the title of some ARTG entries to disappear. We are investigating as a priority and hope to have this resolved as soon as possible.
HYQVIA Takeda Pharmaceuticals Australia Pty Ltd
Product name
HYQVIA
Accepted date
May-2024
Active ingredients
normal immunoglobulin
Proposed indication
For Immunomodulatory therapy in adults and children in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as maintenance therapy after stabilistion with IVIG.
Application type
C (new indication)
Publication date
May-2024